Cortactin is a sensitive biomarker relative to the poor prognosis of human hepatocellular carcinoma

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Zhao, Gang ^a,b   Huang, Zi ming ^c   Kong, Ya Lin ^a   Wen, Dong Qing ^d   Li, Yu ^b   Ren, Li ^a   Zhang, Hong Yi ^a  

^a AIR FORCE GENERAL HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c Post Graduate Institute of An Hui Medical University   (China)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Cortactin; Hepatocellular carcinoma; Neoplasm invasiveness; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CORTACTIN; MESSENGER RNA;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL ASSAY; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; DISEASE SEVERITY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; WOUND HEALING;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CORTACTIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; WOUND HEALING;

EID: 84875142051     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-74     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Chen JG, Zhang SW, Chen WQ. Analysis of liver cancer mortality in the national retrospective sampling survey of death causes in China, 2004-2005. Zhonghua Yu Fang Yi Xue Za Zhi 2010, 44:383-389.
3. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002, 8:385-392.
4. Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, Kawano N, Morioka Y. Postoperative recurrence of hepatocellular carcinoma. Ann Surg 1990, 211:28-33. 10.1097/00000658-199001000-00005, 1357889, 1688488.
5. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 2007, 1773:642-652. 10.1016/j.bbamcr.2006.07.001, 16926057.
6. Chuma M, Sakamoto M, Yasuda J, Fujii G, Nakanishi K, Tsuchiya A, Ohta T, Asaka M, Hirohashi S. Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J Hepatol 2004, 41:629-636. 10.1016/j.jhep.2004.06.018, 15464244.
7. Rodrigo JP, Garcia LA, Ramos S, Lazo PS, Suarez C. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2000, 6:3177-3182.
8. Hui R, Ball JR, Macmillan RD, Kenny FS, Prall OW, Campbell DH, Cornish AL, McClelland RA, Daly RJ, Forbes JF, Blamey RW, Musgrove EA, Robertson JF, Nicholson RI, Sutherland RL. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 1998, 17:1053-1059. 10.1038/sj.onc.1202023, 9747885.
9. Patel AS, Schechter GL, Wasilenko WJ, Somers KD. Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene 1998, 16:3227-3232. 10.1038/sj.onc.1201850, 9681820.
10. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 2006, 66:3034-3043. 10.1158/0008-5472.CAN-05-2177, 16540652.
11. Hofman P, Butori C, Havet K, Hofman V, Selva E, Guevara N, Santini J, Van Obberghen-Schilling E. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status. Br J Cancer 2008, 98:956-964. 10.1038/sj.bjc.6604245, 2266845, 18268492.
12. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255. 10.1016/S0140-6736(11)61347-0, 22353262.
13. Kai M, Irie M, Okutsu T, Inoue K, Ogonuki N, Miki H, Yokoyama M, Migishima R, Muguruma K, Fujimura H, Kohda T, Ogura A, Kaneko-Ishino T, Ishino F. The novel dominant mutation Dspd leads to a severe spermiogenesis defect in mice. Biol Reprod 2004, 70:1213-1221.
14. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
15. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001, 7:1669-1675.
16. Paradis V, Bieche I, Dargere D, Laurendeau I, Laurent C, Bioulac Sage P, Degott C, Belghiti J, Vidaud M, Bedossa P. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol 2003, 163:733-741. 10.1016/S0002-9440(10)63700-5, 1868199, 12875992.
17. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol 2012, 39:410-433. 10.1053/j.seminoncol.2012.05.001, 22846859.
18. Bertino G, Ardiri AM, Calvagno GS, Bertino N, Boemi PM. Prognostic and diagnostic value of des-gamma-carboxy prothrombin in liver cancer. Drug News Perspect 2010, 23:498-508.
19. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006, 131:1758-1767. 10.1053/j.gastro.2006.09.014, 17087938.
20. Wu H, Reynolds AB, Kanner SB, Vines RR, Parsons JT. Identification and characterization of a novel cytoskeleton-associated pp60src substrate. Mol Cell Biol 1991, 11:5113-5124. 361526, 1922035.
21. Schuuring E, Verhoeven E, Litvinov S, Michalides RJ. The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites. Mol Cell Biol 1993, 13:2891-2898. 359682, 8474448.
22. Schuuring E, Verhoeven E, Mooi WJ, Michalides RJ. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 1992, 7:355-361.
23. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003, 78:323-335. 10.1023/A:1023033708204, 12755491.
24. Takes RP, de Jong RJB, Schuuring E, Hermans J, Vis AA, Litvinov SV, van Krieken JH. Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 1997, 123:412-419. 10.1001/archotol.1997.01900040048008, 9109790.
25. Williams ME, Gaffey MJ, Weiss LM, Wilczynski SP, Schuuring E, Levine PA. Chromosome 11Q13 amplification in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1993, 119:1238-1243. 10.1001/archotol.1993.01880230084013, 8217084.
26. Wu H, Parsons JT. Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol 1993, 120:1417-1426. 10.1083/jcb.120.6.1417, 2119758, 7680654.
27. Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 2001, 20:6418-6434. 10.1038/sj.onc.1204783, 11607842.
28. Uruno T, Liu J, Zhang P, Fan Y, Egile C, Li R, Mueller SC, Zhan X. Activation of Arp2/3 complex-mediated actin polymerization by cortactin. Nat Cell Biol 2001, 3:259-266. 10.1038/35060051, 11231575.
29. Weaver AM, Karginov AV, Kinley AW, Weed SA, Li Y, Parsons JT, Cooper JA. Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr Biol 2001, 11:370-374. 10.1016/S0960-9822(01)00098-7, 11267876.
30. Kowalski JR, Egile C, Gil S, Snapper SB, Li R, Thomas SM. Cortactin regulates cell migration through activation of N-WASP. J Cell Sci 2005, 118:79-87. 10.1242/jcs.01586, 15585574.
31. Weaver AM, Heuser JE, Karginov AV, Lee WL, Parsons JT, Cooper JA. Interaction of cortactin and N-WASp with Arp2/3 complex. Curr Biol 2002, 12:1270-1278. 10.1016/S0960-9822(02)01035-7, 12176354.
32. Huang C, Liu J, Haudenschild CC, Zhan X. The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem 1998, 273:25770-25776. 10.1074/jbc.273.40.25770, 9748248.
33. Hill A, McFarlane S, Mulligan K, Gillespie H, Draffin JE, Trimble A, Ouhtit A, Johnston PG, Harkin DP, McCormick D, Waugh DJ. Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. Oncogene 2006, 25:6079-6091. 10.1038/sj.onc.1209628, 16652145.
34. Bryce NS, Clark ES, Leysath JL, Currie JD, Webb DJ, Weaver AM. Cortactin promotes cell motility by enhancing lamellipodial persistence. Curr Biol 2005, 15:1276-1285. 10.1016/j.cub.2005.06.043, 16051170.
35. Timpson P, Lynch DK, Schramek D, Walker F, Daly RJ. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res 2005, 65:3273-3280.
36. Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res 2007, 67:4227-4235. 10.1158/0008-5472.CAN-06-3928, 17483334.
37. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009, 137:850-855. 10.1053/j.gastro.2009.06.003, 2739450, 19524573.
38. Choi KK, Kim SH, Choi SB, Lim JH, Choi GH, Choi JS, Kim KS. Portal venous invasion: the single most independent risk factor for immediate postoperative recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol 2011, 26:1646-1651. 10.1111/j.1440-1746.2011.06780.x, 21592228.
39. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Yu L, Nagasue N. Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma. Surgery 1997, 122:571-577. 10.1016/S0039-6060(97)90130-6, 9308615.
40. Iguchi T, Aishima S, Taketomi A, Nishihara Y, Fujita N, Sanefuji K, Maehara Y, Tsuneyoshi M. Extracapsular penetration is a new prognostic factor in human hepatocellular carcinoma. Am J Surg Pathol 2008, 32:1675-1682. 10.1097/PAS.0b013e31817a8ed5, 18769333.
41. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010, 51:1274-1283. 10.1002/hep.23485, 20112254.